STOCK TITAN

Evaxion swings to $3.54M net loss in Q3 2026

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Evaxion A/S (EVAX) is prioritizing immuno-oncology, including advancing off-the-shelf cancer vaccines EVX-04 and EVX-05 and pursuing partnerships for personalized vaccine EVX-01. The company says it is on track to submit an application for an EVX-04 Phase 1 trial before the end of the year. EVX-01 results showed 89% vaccine target precision, with T-cell and clinical responses sustained at three-year follow-up.

Q3 2026 revenue was zero, versus $7.492 million in Q3 2025, and the company reported a $3.541 million net loss, versus $4.618 million net profit a year earlier. Cash and cash equivalents were $13.274 million as of September 30, 2026. ATM share sales generated $2.2 million in gross proceeds and extended the cash runway toward the end of 2027.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway extended toward the end of 2027 following $2.2 million in gross proceeds from ATM share sales. 9.4% of market cap

Negative

  • Moderate pointQ3 revenue was zero, versus $7.492 million a year earlier.
  • Moderate pointQ3 results shifted from $4.618 million net profit to a $3.541 million net loss.

Filing Explained

At September 30, 2026, equity was $8,143 thousand versus $17,039 thousand at December 31, 2025, reflecting nine-month losses and added ATM proceeds.

Under the announced refocus, future infectious-disease work will proceed only if externally funded, while autoimmune work is focused on concept validation for potential partnerships.

Total equity was $8,143 thousand at September 30, 2026, versus $17,039 thousand at December 31, 2025; Evaxion says the balance reflects nine-month losses and added ATM proceeds.

Q3 revenue $0; $7.492 million in Q3 2025 Three months ended September 30, 2026, compared with the same period in 2025
Q3 net result $3.541 million net loss; $4.618 million net profit in Q3 2025 Three months ended September 30, 2026, compared with the same period in 2025
Cash and cash equivalents $13.274 million As of September 30, 2026
ATM gross proceeds $2.2 million Gross proceeds from ATM share sales
Cash runway Toward the end of 2027 The company said ATM share sales extended its cash runway
EVX-01 vaccine target precision 89% Phase 2 data; three-year follow-up also showed sustained T-cell and clinical responses
Nine-month net loss $10.899 million; $1.789 million in the first nine months of 2025 Nine months ended September 30, 2026, compared with the same period in 2025
Q3 research and development expenses $2.312 million; $3.092 million in Q3 2025 Three months ended September 30, 2026, compared with the same period in 2025
AI-Immunology™ technical
"AI-Immunology™ platform"
ai-immunology™ is the use of artificial intelligence techniques to analyze immune system data and guide the discovery, design and testing of immune-based diagnostics, vaccines and therapies. It matters to investors because it can speed up research, reduce costs and reveal promising drug targets that traditional methods might miss—like using a powerful search engine to find a few needles in a vast haystack of biological signals—potentially increasing the chance and pace of commercial returns.
neoantigens medical
"tumor-specific neoantigens"
Neoantigens are new protein fragments that appear on the surface of diseased cells, most often cancer cells, because of changes in their DNA; the immune system can recognize these as foreign. For investors, neoantigens matter because they are targets for precision therapies and vaccines that aim to teach the immune system to attack only diseased cells—think of them as unique fingerprints that enable treatments to be more specific and potentially more effective, which can drive clinical and commercial value.
endogenous retrovirus (ERV) tumor antigens medical
"multiple non-conventional endogenous retrovirus (ERV) tumor antigens"
At-The-Market (ATM) equity program financial
"utilization of our At-The-Market (ATM) equity program"
An at-the-market (ATM) equity program lets a company sell newly issued shares directly into the open market over time at the current trading price through a broker, rather than all at once. Think of it like drip-feeding new product into a store at whatever the going price is; it provides flexible, immediate fundraising but can reduce each existing shareholder’s ownership percentage and influence trading supply and share price, so investors watch how much and how often the company uses it.
IND-enabling studies medical
"advance preclinical IND-enabling studies"
Ind-enabling studies are early research efforts that test whether a new drug or treatment is safe and effective enough to move forward in development. They are like preliminary tests to ensure a product works as intended before investing more resources into large-scale trials. For investors, these studies are important because successful results can signal potential progress toward bringing a new product to market, impacting its future value.
dark genome technical
"mining novel sources from the dark genome"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were EVAX’s Q3 2026 revenue and net result?

EVAX reported zero revenue and a $3.541 million net loss in Q3 2026. In Q3 2025, it reported $7.492 million in revenue and a $4.618 million net profit.

When does EVAX expect to submit EVX-04 for a Phase 1 trial?

Evaxion says it is on track to file the EVX-04 Phase 1 trial application before the end of the year. It also announced a planned presentation of new EVX-04 target-validation data at the ASH Annual Meeting in New Orleans, December 12–15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]


INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On November 19, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion announces strategy and business update and third quarter 2026 financial results". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit Number Description
   
99.1 Evaxion announces strategy and business update and third quarter 2026 financial results


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

   Evaxion A/S
   (Registrant)
    
   
Date: November 19, 2026 By:/s/ Helen Tayton-Martin    
   Helen Tayton-Martin
   Chief Executive Officer
   

EXHIBIT 99.1

Evaxion announces strategy and business update and third quarter 2026 financial results

COPENHAGEN, Denmark, November 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, provides strategy and business update and announces third quarter 2026 financial results.

Strategy update
Evaxion is refocusing its strategy to prioritize its immuno-oncology assets and capabilities, fully leveraging AI-Immunology™ in novel cancer target discovery and cancer vaccine development.

The aim is to maximize the value given clinical validation of the platform in personalized cancer vaccines with EVX-01 and the broader opportunity with off-the-shelf cancer vaccines in multiple indications through access to a wider diversity of novel antigens, including but not limited to endogenous retroviruses (ERVs).

Going forward, Evaxion will focus its R&D portfolio by:

  • Advancing off-the-shelf cancer vaccines EVX-04 and EVX-05 towards clinical development
  • Expanding personalized cancer vaccine EVX-01’s potential in multiple indications via partnerships
  • Continuing to identify new cancer vaccine targets for further development by mining novel sources from the dark genome
  • Working through partnerships on our preclinical portfolio of infectious disease assets
  • Completing validation on the autoimmune concepts we have developed with AI-Immunology™ for future partnerships

As a result of the refocused strategy, Evaxion will make some adjustments to its organization.

“We are refocusing our strategy on the unique capabilities of AI-Immunology™ in discovery and design of novel cancer vaccines. Evaxion’s AI-Immunology™ platform has recently been further validated by stronger clinical and translational datasets from the phase 2 trial with EVX-01 in advanced melanoma at a time when the entire landscape around personalized cancer vaccines has changed more positively. With the ability to also produce off-the-shelf cancer vaccines, we are maintaining strong operational momentum on all of our milestones for the year, tracking towards achieving the last one with the EVX-04 off-the-shelf vaccine clinical trial submission, as we re-focus our efforts towards immuno-oncology”, says Helen Tayton-Martin, CEO of Evaxion.

Business highlights (since last quarterly update)

  • Presentation of three-year clinical outcome and immune data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 and additionally new phase 2 biomarker data at SITC 2026
  • Announcing the upcoming presentation of new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting
  • Winning the 2026 International Prix Galien Award for Best digital health solution for AI-Immunology™
  • Our cash runway has been extended towards the end of 2027

Conference call and webcast
Evaxion’s executive management will host a conference call and webcast at 8.30am ET/14.30 CET today, presenting the business update and financial results as well as taking questions.

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.

Research & Development (R&D) update
Evaxion has a R&D pipeline of innovative vaccine candidates for both cancer and infectious diseases and has recently made progress in both areas.

Most notably, we have presented new phase 2 data for personalized cancer vaccine EVX-01, our most advanced pipeline asset, at both the European Society for Medical Oncology (ESMO) and Society for Immunotherapy of Cancer (SITC) congresses.

Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient's immune system to attack the cancer by mounting a targeted response against tumor-specific neoantigens.

EVX-01 is intended for first-line treatment of multiple advanced solid cancer tumors and has, in the phase 2 trial, been evaluated as a treatment of advanced melanoma. The recent data shows an 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up.

The very high precision rate is another confirmation that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. Thus, the new data supports both EVX-01 as a promising personalized cancer vaccine and AI-Immunology™ as a validated technology for discovery and design of novel cancer treatments.

Further to the personalized approach, we are leveraging AI-Immunology™ to develop novel off-the-shelf cancer vaccines, including EVX-04 targeting AML. Developed with AI-Immunology™, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.

We are on track to file the application for a phase 1 trial with EVX-04 before the end of the year and continue to advance preclinical IND-enabling studies and expand the data package. We are very much looking forward to presenting new target validation data for EVX-04 at the important American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026.

Within infectious diseases we have achieved the milestone of designing and preclinically validating antigens to be included in EVX-B4, a novel vaccine candidate for Group A Streptococcus. As per our refocused strategy, we will only conduct future work on our infectious disease programs if funded by external partners and will continue to proactively pursue relevant partnership opportunities.

We have also recently presented AI-Immunology™ derived novel therapeutic concepts for autoimmune diseases. Our future activities in this space will be focused on concept validation for potential future partnerships.

Business development update
We remain active in multiple parallel partnership discussions based on external interest in both AI-Immunology™ and our R&D pipeline based on the strong clinical validation of our platform and as we continue to pursue our strategy of developing novel IO assets and strengthening our platform through strategic partnerships.

We were honored to receive the prestigious International Prix Galien Award for AI-Immunology™ as best digital health solution in October. The award is another strong external validation and recognition of the AI-Immunology™ platform in generating key data confirming the fact that AI-Immunology™ is a platform that delivers meaningful therapeutic product candidates. This is an important distinction with potential business partners.

Third quarter 2026 financial results
We have extended our cash runway towards the end of 2027 through utilization of our At-The-Market (ATM) equity program selling Evaxion shares resulting in gross proceeds of $2.2 million improving our cash at hand and equity.

Earlier in November, we filed an amendment to the registration statement on Form F-1 related to the 2025 debt settlement agreement with The European Investment Bank (EIB) with the US Securities and Exchange Commission.

The registration statement was originally filed in November 2025, as required under the agreement under which EIB converted debt to warrants, and relates solely to the possible resale by EIB of shares issuable upon exercise of those warrants. We are not conducting a capital raise.

The financial results for the third quarter 2026 were in line with expectations with a net loss of $3.5 million, compared to loss of $3.7 million in the second quarter 2026 and a profit of $4.6 million in the third quarter 2025.

Compared to same period last year where we recorded revenue from out-licensing EVX-B3 to MSD, no revenue has been recorded in Q3 2026, while we have reduced cost in the quarter compared to last year primarily relating to lower personnel expenses and capital market costs, and our net financial expenses reflects normalized financial income and expenses.

Research and development (R&D) expenses were $2.3 million for the third quarter 2026, aligned with second quarter 2026, and a reduction compared to third quarter last year, mainly due to reduced headcount.

General and administrative (G&A) expenses were $1.4 million for the quarter, level with second quarter 2026, and compared to $1.4 million in second quarter 2025. Compared to last year we have lower capital market cost compensated by higher business development costs.

Net financial expense of $0.1 million for the third quarter 2026 compared to net financial income of $1.3 million same quarter last year. The third quarter 2026 reflects our normalized business, and where Q3 last year was impacted by financial income from debt settlement agreement with EIB and financial expenses from a significant higher derivative liability.

Cash and cash equivalents as of September 30, 2026, were $13.3 million, compared to $14.0 million as of June 30, 2026, extending our current cash runway towards the end of 2027.

Total equity amounts to $8.1 million as of September 30, 2026, reflecting the net loss of the first nine months of 2026 and added the proceeds from ATM sales, when compared to $17.0 million as of December 31, 2025.

Evaxion A/S
(Unaudited) Consolidated statement of financial position data
(USD in thousands)

 Sep 30,
2026
Dec 31,
2025
Cash and cash equivalents13,27423,234
Total assets18,66528,408
Total liabilities10,52311,369
Share capital17,12915,791
Other reserves130,301127,492
Accumulated deficit(139,288)(126,244)
Total equity8,14317,039
Total liabilities and equity18,66528,408


Evaxion A/S
(Unaudited) Consolidated statement of comprehensive loss data
(USD in thousands, except per share data)

 Three Months Ended
Sep 30,
Nine Months Ended
Sep 30,
 2026202520262025
Revenue-7,492-7,528
Research and development(2,312)(3,092)(6,943)(7,415)
General and administrative(1,361)(1,377)(4,394)(5,295)
Operating profit/(loss)(3,673) 3,022(11,338) (5,182)
Finance income1522,6905575,729
Finance expenses(212)(1,360)(730)(2,988)
Net profit/(loss) before tax(3,732) 4,352(11,511) (2,442)
Income tax benefit191265611652
Net profit/(loss) for the period(3,541) 4,618(10,899) (1,789)
Net loss attributable to shareholders of Evaxion A/S(3,541) 4,618(10,899) (1,789)
Loss per share – basic and diluted(0.01)0.01(0.03)(0.01)
Number of shares used for calculation (basic and diluted)431,856,012318,041,649422,013,554289,792,967


Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. Evaxion harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer. Through partnerships AI-Immunology™ can also be applied in infectious and autoimmune diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

Filing Exhibits & Attachments

1 document

Keep reading